Recently, the results of the ATLANTIC trial [17, 18] showed the possible efficacy of durvalumab (anti-human PD-1 monoclonal antibodies) as a third-line (or later) treatment for advanced NSCLC, including EGFR+/ALK+ NSCLC. Here, ALK is linked to non-small cell lung carcinoma.